title: Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.
abstract: Multi-agent chemotherapy is the standard treatment for most B cell malignancies. Since chemotherapy can be associated with significant toxicity and since relapses resistant to chemotherapy often develop, new therapies are needed. Blinatumomab (AMG 103 or MT103) is a late-stage candidate in clinical development, which belongs to a novel class of antibody constructs termed bi-specific T cell engager antibodies. This antibody construct has dual specificity for CD19 and CD3 and can re-direct polyclonal cytotoxic T lymphocytes toward the tumor. This review focuses on the pre-clinical and clinical development of blinatumomab as a powerful new tool in the treatment of B cell malignancies.
authors.affiliation: Global Development, Amgen Inc., Thousand Oaks, CA 91320, USA zacharyz@amgen.com.
authors.forename: Zachary
authors.initials: Z
authors.lastname: Zimmerman
authors.affiliation: Global Development, Amgen Inc., Thousand Oaks, CA 91320, USA.
authors.forename: Tapan
authors.initials: T
authors.lastname: Maniar
authors.affiliation: Global Development, Amgen Inc., Thousand Oaks, CA 91320, USA.
authors.forename: Dirk
authors.initials: D
authors.lastname: Nagorsen
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017252:CD3 Complex / Q000276:immunology; D002986:Clinical Trials as Topic; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation / Q000187:drug effects; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000951:Antigens, Neoplasm; D017252:CD3 Complex; C510808:blinatumomab
keywords: BiTE®; bi-specific antibody; immunotherapy; leukemia; lymphoma